Inoperable Chronic Thromboembolic Pulmonary Hypertension: Evolution of Prognosis over 10 Years of New Emerging Therapies

Overview

Journal Pulm Circ

Publisher Wiley

Specialty Pulmonary Medicine

Date 2024 Aug 23

PMID 39175520

Authors

Diederik P Staal

Paul M Hendriks

Mitch C J van Thor

Liza D van de Groep

Leon M van den Toorn

Berend-Jan M Mulder

Prewesh P Chandoesing

Robert M Kauling

Sanne Boerman

Annemien E van den Bosch

Johannes J Mager

Karin A Boomars

Martijn C Post

Affiliations

Soon will be listed here.

Abstract

Therapies for inoperable chronic thromboembolic pulmonary hypertension (CTEPH) include balloon pulmonary angioplasty (BPA) and PH-specific medical therapy. This study compares survival and its predictors before and after the introduction of BPA. BPA was independently associated with survival; however, there was no difference in overall survival between the two cohorts.

References

Wiedenroth C, Rolf A, Steinhaus K, Adameit M, Kriechbaum S, Haas M . Riociguat and balloon pulmonary angioplasty improve prognosis in patients with inoperable chronic thromboembolic pulmonary Hypertension. J Heart Lung Transplant. 2022; 42(1):134-139. DOI: 10.1016/j.healun.2022.08.011. View

Taniguchi Y, Jais X, Jevnikar M, Boucly A, Weatherald J, Brenot P . Predictors of survival in patients with not-operated chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant. 2019; 38(8):833-842. DOI: 10.1016/j.healun.2019.04.006. View

Delcroix M, Lang I, Pepke-Zaba J, Jansa P, DArmini A, Snijder R . Long-Term Outcome of Patients With Chronic Thromboembolic Pulmonary Hypertension: Results From an International Prospective Registry. Circulation. 2016; 133(9):859-71. DOI: 10.1161/CIRCULATIONAHA.115.016522. View

Ghofrani H, DArmini A, Grimminger F, Hoeper M, Jansa P, Kim N . Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013; 369(4):319-29. DOI: 10.1056/NEJMoa1209657. View

Ghofrani H, Simonneau G, DArmini A, Fedullo P, Howard L, Jais X . Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. Lancet Respir Med. 2024; 12(4):e21-e30. DOI: 10.1016/S2213-2600(24)00027-4. View

Escribano-Subias P, Blanco I, Lopez-Meseguer M, Lopez-Guarch C, Roman A, Morales P . Survival in pulmonary hypertension in Spain: insights from the Spanish registry. Eur Respir J. 2012; 40(3):596-603. DOI: 10.1183/09031936.00101211. View

Lang I, Andreassen A, Andersen A, Bouvaist H, Coghlan G, Escribano-Subias P . Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: a clinical consensus statement of the ESC working group on pulmonary circulation and right ventricular function. Eur Heart J. 2023; 44(29):2659-2671. PMC: 10393078. DOI: 10.1093/eurheartj/ehad413. View

van Thor M, Lely R, Braams N, Ten Klooster L, Beijk M, Heijmen R . Safety and efficacy of balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension in the Netherlands. Neth Heart J. 2019; 28(2):81-88. PMC: 6977797. DOI: 10.1007/s12471-019-01352-6. View

Galie N, Humbert M, Vachiery J, Gibbs S, Lang I, Torbicki A . 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS):.... Eur Heart J. 2015; 37(1):67-119. DOI: 10.1093/eurheartj/ehv317. View

10.

Ling Y, Johnson M, Kiely D, Condliffe R, Elliot C, Gibbs J . Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. Am J Respir Crit Care Med. 2012; 186(8):790-6. DOI: 10.1164/rccm.201203-0383OC. View

11.

Mizoguchi H, Ogawa A, Munemasa M, Mikouchi H, Ito H, Matsubara H . Refined balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv. 2012; 5(6):748-55. DOI: 10.1161/CIRCINTERVENTIONS.112.971077. View

12.

Sablinskis K, Sablinskis M, Lejnieks A, Skride A . Growing number of incident pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension patients in Latvia: a shifting epidemiological landscape? Data from a national pulmonary hypertension registry. Eur J Intern Med. 2018; 59:e16-e17. DOI: 10.1016/j.ejim.2018.09.017. View

13.

Rosenkranz S, Channick R, Chin K, Jenner B, Gaine S, Galie N . The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study. Eur J Heart Fail. 2021; 24(1):205-214. PMC: 9298818. DOI: 10.1002/ejhf.2369. View

14.

van Thor M, Snijder R, Kelder J, Mager J, Post M . Does combination therapy work in chronic thromboembolic pulmonary hypertension?. Int J Cardiol Heart Vasc. 2020; 29:100544. PMC: 7270605. DOI: 10.1016/j.ijcha.2020.100544. View

15.

Humbert M, Kovacs G, Hoeper M, Badagliacca R, Berger R, Brida M . 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022; 43(38):3618-3731. DOI: 10.1093/eurheartj/ehac237. View

16.

Simonneau G, Torbicki A, Dorfmuller P, Kim N . The pathophysiology of chronic thromboembolic pulmonary hypertension. Eur Respir Rev. 2017; 26(143). PMC: 9488693. DOI: 10.1183/16000617.0112-2016. View

17.

Jenkins D, Madani M, Fadel E, DArmini A, Mayer E . Pulmonary endarterectomy in the management of chronic thromboembolic pulmonary hypertension. Eur Respir Rev. 2017; 26(143). PMC: 9489144. DOI: 10.1183/16000617.0111-2016. View